The Science of Glaucoma Management: From Translational Research to Next-Generation Clinical Practice
Editat de Kevin Gillmann, Kaweh Mansourien Limba Engleză Paperback – 22 mai 2023
The book allows glaucoma specialists to explore novel ways to refine and rethink their practice based on the latest discoveries in basic sciences and breakthrough technologies, and to gain a better understanding on how their specialty is evolving and how research may shape tomorrow’s practice.
- Presents a detailed report on the latest translational research and breakthroughs that may transform glaucoma practice
- Overviews the specialty from a scientific and clinical point-of-view
- Written by world-renowned clinicians and researchers in the field of glaucoma
- Includes insights, opinions and recommendations from some of the most prominent scientists and ophthalmologists
- Covers hot topics and the latest technologies in glaucoma, such as minimally invasive glaucoma surgery, telemedicine, gene therapy, neuroprotection and artificial intelligence
Preț: 750.46 lei
Preț vechi: 978.10 lei
-23% Nou
Puncte Express: 1126
Preț estimativ în valută:
143.62€ • 151.08$ • 119.84£
143.62€ • 151.08$ • 119.84£
Carte tipărită la comandă
Livrare economică 03-17 ianuarie 25
Livrare express 05-11 decembrie pentru 113.05 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780323884426
ISBN-10: 0323884423
Pagini: 482
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 216 x 276 x 29 mm
Greutate: 1.31 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0323884423
Pagini: 482
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 216 x 276 x 29 mm
Greutate: 1.31 kg
Editura: ELSEVIER SCIENCE
Public țintă
Primary: Glaucoma researchers, glaucoma specialists who seek to understand the basic sciences underlying recent and future breakthrough in their specialty, and to refine their clinical practice.Secondary: General ophthalmologists seeking to vastly deepen their knowledge of glaucoma management. Bioengineering and physiological research scientists, both established and in training, seeking to work in the field of glaucoma will constitute a secondary market.
Cuprins
Part 1: Currently Accepted Glaucoma Practice
1. Pathophysiology
2. Epidemiology
3. Diagnosis and investigations
4. Follow-up
5. Treatments
6. Section Summary: Discussion on the major unmet needs of the specialty
Part 2: Pathophysiology and investigation methods
7. Glaucoma epidemiology: the role of genetics and biomarkers
8. Considerations for an efficient screening programmes for glaucoma
9. Ocular perfusion in glaucoma and the role of arterial blood pressure
10. The role of circadian and extrinsic intraocular pressure fluctuations
11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact
12. Retinal and optic nerve micro-perfusion and the role of OCT-A
13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density?
14. Statistical considerations on visual field testing: how frequent is frequent-enough?
15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision
16. Section Summary: Diagnosing the grey zone and follow-up considerations
Part 3: Medical and laser therapies
17. Social and psychological aspects of treatment adherence
18. Topical medications and ocular surface
19. Novel pressure-lowering medications and research alternatives
20. Novel drug delivery methods
21. Matrix metalloproteinase
22. Medical lasers, basic principles and core differences
23. Physiological principles and effects of SLT; discussion over the LIGHT Trial
24. Prophylactic iridotomy in narrow angle glaucoma
25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies)
26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations
Part 4: Surgical options
27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma
28. Anatomical considerations on trabecular meshwork, Schlemm’s canal and collecting channels
29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery)
30. Aqueous angiography and targeted surgery
31. Minimally-invasive glaucoma surgery (MIGS) device design considerations
32. Novel approaches to aqueous drainage
33. Adjustable drainage devices: benefits and shortcomings
34. Implantable intraocular pressure sensors and telemedicine
35. Laser-assisted surgery
36. Considerations on glaucoma clinical trials
37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure match
Part 5: New technologies
38. Artificial intelligence and Big Data: technical considerations and clinical applications
39. Detection of apoptosing retinal cells (DARC) in glaucoma
40. Neuroprotection and neurostimulation
41. Clinical trials in neuroprotection: special considerations
42. Neuro-regeneration and stem-cell therapies
43. Gene therapy
44. Section Summary: Predicting the future of glaucoma practice
1. Pathophysiology
2. Epidemiology
3. Diagnosis and investigations
4. Follow-up
5. Treatments
6. Section Summary: Discussion on the major unmet needs of the specialty
Part 2: Pathophysiology and investigation methods
7. Glaucoma epidemiology: the role of genetics and biomarkers
8. Considerations for an efficient screening programmes for glaucoma
9. Ocular perfusion in glaucoma and the role of arterial blood pressure
10. The role of circadian and extrinsic intraocular pressure fluctuations
11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact
12. Retinal and optic nerve micro-perfusion and the role of OCT-A
13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density?
14. Statistical considerations on visual field testing: how frequent is frequent-enough?
15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision
16. Section Summary: Diagnosing the grey zone and follow-up considerations
Part 3: Medical and laser therapies
17. Social and psychological aspects of treatment adherence
18. Topical medications and ocular surface
19. Novel pressure-lowering medications and research alternatives
20. Novel drug delivery methods
21. Matrix metalloproteinase
22. Medical lasers, basic principles and core differences
23. Physiological principles and effects of SLT; discussion over the LIGHT Trial
24. Prophylactic iridotomy in narrow angle glaucoma
25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies)
26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations
Part 4: Surgical options
27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma
28. Anatomical considerations on trabecular meshwork, Schlemm’s canal and collecting channels
29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery)
30. Aqueous angiography and targeted surgery
31. Minimally-invasive glaucoma surgery (MIGS) device design considerations
32. Novel approaches to aqueous drainage
33. Adjustable drainage devices: benefits and shortcomings
34. Implantable intraocular pressure sensors and telemedicine
35. Laser-assisted surgery
36. Considerations on glaucoma clinical trials
37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure match
Part 5: New technologies
38. Artificial intelligence and Big Data: technical considerations and clinical applications
39. Detection of apoptosing retinal cells (DARC) in glaucoma
40. Neuroprotection and neurostimulation
41. Clinical trials in neuroprotection: special considerations
42. Neuro-regeneration and stem-cell therapies
43. Gene therapy
44. Section Summary: Predicting the future of glaucoma practice